#1Investor Presentation December 2022 Moolec TM SCIENCE IN ALTERNATIVE PROTEINS#2Disclaimer This presentation was prepared for informational purposes only by Moolec Science Limited, ("Moolec") and LightJump Acquisition Corporation ("LightJump") and is intended to be provided only to accredited institutional investors who are considering an investment in Moolec. The information provided in this presentation is intended to highlight certain matters bearing upon the current status of Moolec that may be of interest to potential investors. The information is not complete, comprehensive or exhaustive, and any potential investor wishing to obtain additional information about topics referenced in the presentation, or other matters in connection with a potential investment, is encouraged to contact Moolec. Forward-Looking Statements This presentation includes "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, statements concerning the following include forward looking statements: the growth of Moolec's business and its ability to realize expected results; the business model of Moolec relating to any partnerships, commercial contracts, regulatory approvals or patent filings; the viability of its growth and commercial strategy; financial projections; the success, cost and timing of its product development abilities; the advantages and potential of Moolec's technology and products, including in comparison to competing technologies and products; trends and developments in the industry; the addressable market; the contemplated transaction among Moolec and LightJump; Moolec's addressable market; and the potential effects of the business combination among Moolec and LightJump. Such forward- looking statements with respect to performance, prospects, revenues and other aspects of the business of Moolec or LightJump are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. These factors include, but are not limited to: (1) the inability to complete the transactions contemplated by the proposed business combination, resulting in a combined company with the expectation to be listed on Nasdaq (the “Combined Company”); (2) the inability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, and the ability of the combined business to grow and manage growth profitably; (3) the inability to successfully retain or recruits officers, key employees, or directors following the proposed business combination; (4) effects on LightJump's public securities' liquidity and trading; (5) the market's reaction to the proposed business combination; (6) the lack of a market for LightJump's securities; (7) Moolec's and LightJump's financial performance following the proposed business combination; (8) costs related to the proposed business combination; (9) changes in applicable laws or regulations; (10) the possibility that LightJump or Moolec may be adversely affected by other economic, business, and/or competitive factors; (11) the risk that Moolec is unable to successfully develop and commercialize Moolec's products or services or experience significant delays; (12) the risk of product liability or regulatory lawsuits relating to Moolec's products and services; (13) the risk that Moolec is unable to secure or protect its intellectual property; (14) the ability to maintain the listing of LightJump's securities on Nasdaq and (15) the ability for the Combined Company's securities to be approved for listing on Nasdaq or if approved, maintain the listing. The foregoing list of factors is not complete or exhaustive. You should carefully consider the foregoing factors as well as other risks and uncertainties described in the "Risk Factors" section of LightJump's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in the final prospectus of LightJump related to its initial public offering filed with the Securities and Exchange Commission ("SEC"). You should also carefully consider the other risks and uncertainties indicated from time to time in documents filed or to be filed with the SEC by LightJump and the Form F-4 and proxy statement to be filed with the SEC by the Combined Company and LightJump. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Forward-looking statements speak only as of the date they are made. Accordingly, you should not put undue reliance on these statements. Industry and Market Data; Trademarks and Trade Names In this presentation, Moolec and LightJump rely on and refer to information and statistics regarding the market in which Moolec competes and other industry data. Moolec and LightJump obtained this information and statistics from third-party sources, including reports by market research firms. Accordingly, none of Moolec, LightJump nor their respective affiliates and advisors makes any representations as to the accuracy or completeness of these data. Moolec and LightJump have supplemented this information where necessary with information from Moolec's own internal estimates, taking into account publicly available information about other industry participants and Moolec's management's best view as to information that is not publicly available. Moolec and LightJump also own or have rights to various trademarks, service marks and trade names that they use in connection with the operation of their respective businesses. This presentation also contains trademarks, service marks and trade names of third parties, which are the property of their respective owners. The use or display of third parties trademarks and Moolec or LightJump use thereof does not imply an affiliation with, or endorsement by the owners of such trademarks, copyrights, logos and other intellectual property. Solely for convenience, the trademarks, service marks and trade names referred to in this presentation may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that Moolec or LightJump will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks and trade names. Moolec takes all necessary action to respect all intellectual property rights. No Offer or Solicitation This presentation is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. Confidentiality All recipients agree that they will keep confidential all information contained herein and not already in the public domain and will use this presentation solely for evaluation purposes. Recipient will maintain all such information in strict confidence, including in strict accordance with any underlying contractual obligations and all applicable laws, including United States federal and state securities laws. This presentation is not intended to constitute and should not be construed as investment advice and does not constitute investment, tax, or legal advice. Important Information About the Business Combination and Where to Find It In connection with the proposed transaction, the Combined Company, which is expected to become the holding company of LightJump and Moolec as of the closing of the proposed transaction, filed a registration statement on Form F-4 (the "Form F-4") with the SEC that includes a proxy statement of LightJump that will also constitute a prospectus of the Combined Company. Moolec, the Combined Company and LightJump urge investors, stockholders and other interested persons to read, when available, the Form F-4, including the preliminary proxy statement/prospectus and amendments thereto and the definitive proxy statement/prospectus and documents incorporated by reference therein, as well as other documents filed with the SEC in connection with the proposed transaction, as these materials will contain important information about Moolec, the Combined Company, LightJump and the proposed transaction. After the registration statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement will be mailed to shareholders of LightJump as of a record date to be established for voting on the proposed business combination. Once available, shareholders will also be able to obtain a copy of the Form F-4, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to: 2735 Sand Hill Road, Suite 110, Menlo Park, CA 94025. The preliminary and definitive proxy statement/prospectus to be included in the registration statement, once available, can also be obtained, without charge, at the SEC's website (www.sec.gov). Participants in the Solicitation Moolec and Lightjump and their respective directors and executive officers may be considered participants in solicitation of proxies with respect to the proposed business combination described in this presentation under the rules of the SEC. Information about the directors and executive officers of LightJump is set forth in LightJump's final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the "Securities Act") on January 12, 2021, and is available free of charge at the SEC's website at www.sec.gov or by directing a request to: 2735 Sand Hill Road, Suite 110, Menlo Park, CA 94025. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the LightJump stockholders in connection with the proposed business combination will be set forth in the registration statement containing the proxy statement/prospectus for the proposed business combination when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above. TM SCIENCE IN Moolec ALTERNATIVE PROTEINS .02#3TM Moolec SCIENCE IN ALTERNATIVE PROTEINS Planting the Future of Food 888 Moolec Moolec is a science-based food ingredient company focused on the use of Molecular Farming technology. Our purpose is to upgrade taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. .03#4Business Model Moolec's innovation starts at the beginning of the food value chain. Modified Seeds ㅎㅎ Contracted Growers & Downstream Moolec's IP TM Moolec SCIENCE IN ALTERNATIVE PROTEINS Animal Protein Moolec Plant-based Ingredients TM B2B Food Producers & Ath Model CPG Companies Retail / Food Services Consumers Ingredient Companies Partnership or Licensing .04#5Crop Science & Cultivation Moolec's Operations We operate through hubs in established locations where cutting-edge R&D and science services are provided, and optimal natural conditions for crop development are present. Washington State University WISCONSIN CROP WINNOVATION CENTER TM Moolec Back Office & Cultivation 0 Inmet INDEAR AGRALITY 00 SCIENCE IN ALTERNATIVE PROTEINS Industrial Hub 3 CHEMO O Food Science Hub future FLAVOUR foods products Molecular Biology محمد سے artes Premas Biotech .05#6TM Moolec World Class Management Team Top Ph.Ds and recognized professionals that come from all over the world conform Moolec's team in line with our global ambitions and targeted footprint. Gastón Paladini, MBA Chief Executive Officer 20+ years in marketing and the traditional food industry as a Director of Paladini Group, one of the largest meat production players in Argentina. Henk Hoogenkamp, Ph.D Chief Product Officer 15 years in food and bio-materials applications with special focus on animal and plant-based proteins. Amit Dhingra, Ph.D Chief Science Officer 20+ years in genomics and plant biotechnology. Prof. and Head, Department of Horticultural Sciences, Texas A&M University. 10+ years of corporate leadership. José López Lecube, MBA Chief Financial Officer 15 years in strategic roles for multinational companies in agribusiness and tech with expertise in finance, strategy, and partnerships. Martín Salinas, Ph.D Chief of Technology 15+ years in engineering and Ag-biotech space leading the world's first industrial production of animal protein in plants for the food industry. Catalina Jones, B.A. Chief of Staff & Sustainability 10+ years in communications, accountability, and sustainability management for financial, agribusiness, packaging, and food industry. SCIENCE IN ALTERNATIVE PROTEINS David Heron, Ph.D Regulatory Affairs 30+ years in the biotechnology regulatory program of USDA-APHIS focused on policy development, training, public communication, and capacity building in agricultural biotechnology. Martín Taraciuk, M.Fin Investor Relations 8+ years in investor relations roles for public listed companies in real estate, agribusiness and energy, capital market transactions, finance, M&A, valuations, and corporate finance. Bruce Williamson, Ph.D Sr. Plant Biologist 10+ years of research experience and a strong background in molecular plant sciences, plant breeding, and biotechnology. Vivek Narisetty, Ph.D Sr. Molecular Biologist 7+ years in process development for value-added chemicals, strain and media engineering, bioreactor scale-up and downstream processing. .06#7BIOCERES 2 100.0% О ΤΗΕΟ IN THE LIGHT OF EVOLUTION Bioceres Crop Solutions (NASDAQ:BIOX) 4.7% 3 80.0% BG Farming Technologies Ltd. TM SCIENCE IN Moolec ALTERNATIVE PROTEINS Pro-Forma Ownership' The Biotech Company LLC' 20.0% 37.0% ល UNION GROUP IIII 5 37.0% New Company Shareholders6 9 TM Moolec Initial Stockholders 7 3.8% 6.5% LJAQ Public Stockholders 7.0% Other Investors 8 Pre de-SPAC shareholders New Shareholders 1 Assumes no LJAQ Public Stockholders exercise redemption rights in connection with the business combination; actual redemptions may differ. For a complete description of all the assumptions applicable to this chart, please refer to "Appendix - Latest Detail Pro-Forma Ownership" 2 Bioceres Group PLC 3 Bioceres Group venture vehicle 6 Reflects certain shareholders of Bioceres S.A. and Bioceres Group PLC that will receive a new issuance of Company Ordinary Shares, prior to the business combination, that will be exchanged for Holdco Ordinary Shares 7 Refers to LJAQ Sponsor shares and ordinary shares issued to EarlyBird in connection with the IPO 8 Includes shares from Moolec SAFE holders that entail Theo I SCSp, third-party investors, and shares from other equity commitments 9 Moolec Science SA, the combined company following the completion of the business combination .07 4 Moolec Science Ltd. CEO Holdco 5 Refers to Union Group Ventures Ltd. 3.9%#8TM Moolec Moolec by the Numbers The company is pioneering the future of alternative protein production with Molecular Farming technology. $65B Total Addressable Market (2025E)1 1st Team to achieve a bovine protein with plants for food² 20+ Global Patents & Patent Applications³ 60x Less GHG Emissions vs. Cattle Farming4 35x Less Land Usage vs. Cattle Farming5 100% Cruelty-Free 10+ Years of Propietary Research & Development² 4 Key Alliances with crop science and pharmaceutical players. 8 Signed Contracts, MOUs & MTAs with Food Producers SCIENCE IN ALTERNATIVE PROTEINS 1 Moolec's internal analysis based on publicly disclosed information for the industry, primarily the GFI State of Industry Report 2021 (March 2022) 2 This milestone was achieved by a Team within Bioceres Group, Moolec's predecessor company 3 Both granted and pending 4 https://ourworldindata.org/food-choice-vs-eating-local 5 https://ourworldindata.org/agricultural-land-by-global-diets .08#9A spin-off from Bioceres Group Bioceres transferred full ownership of patents and 10+ years experience in Molecular Farming technology to form a standalone, food-science-focused company. Science for a sustainable agriculture (Bioceres S.A. Private entity) TM SCIENCE IN Moolec ALTERNATIVE PROTEINS Scientific Team + Intellectual Property Science applied to alternative proteins Moolec TM Newly formed management and scientific leadership .09#10Moolec's Pathway to Public Listing 10 years building our technology Lab Pilot plant 2008 TM SCIENCE IN Moolec ALTERNATIVE PROTEINS Technology scale-up SPC Patents Approvals Industrial Scale Spin-off (UK Entity) From Safflower to Soy Company Building Expected Listing INTE PATENTED PROPERTY 2014 Proof of Concept BIOCERES (Bioceres S.A. - Private entity) TM Moolec 2018 2020 2021 GLA IP Incorporation Bioceres Crop Solutions (NASDAQ:BIOX) Nasdaq 2022 .10#11TM Moolec Backers & Partners Moolec's shareholders and strategic partners bring key experience, advisory, scientific know-how, and access to facilities to strengthen the business. Science + Operations Finance ה Bioceres Crop Solutions Provider of ag-tech solutions enabling the transition towards carbon neutrality • Facilities, Fields & Farmers • IP + Legal Team UNION GROUP |||| Union Group is a privately owned invest-ment and private equity management firm established in 2007. These cover the agricultural, energy, forestry, infrastructure, minerals, oil & gas and real estate sectors. • Tech Services SCIENCE IN ALTERNATIVE PROTEINS Molecular Biology + Scale Up grupoINSUD Strategic Joint Venture • Global presence • Commitment in developing long- term, innovative, and sustainable projects. • Business: Life Sciences Information & Culture o Agribusiness O 。 Nature & Design .11#12Why Moolec? 01 Category creators: science-based & high-value added company pioneer of the 4th technological pillar within the alternative protein industry. 021 Massive addressable market: sizeable TAM1 and industry trends support significant growth opportunities. 03 Unmatched value proposition: advantages include lower cost, higher scale, and better organoleptic experience. $$$ 个 04 Highly experienced team: visionary leadership team with unparalleled expertise in the Molecular Farming category, ingredients, and food industry. 05 J☀E ESG pure play: Moolec works towards 10 out of the 17 the SDGs within an industry that creates an environmentally positive impact. 06 도 Long-standing backers: endorsed by leading companies in biotech & life sciences, finance, and molecular biology. TM SCIENCE IN 1 Refers to Total Addressable Market Moolec ALTERNATIVE PROTEINS .12#13The Industry Moolec TM SCIENCE IN ALTERNATIVE PROTEINS 元#14Economic¹ Food Crisis: Ring of Fire Weakness of global food supply chain is on the spotlight due to present context. es $ Environmental³ 900 Nutrition5 TTT Pests & Diseases oo War in Ukraine is amplifying global food crisis². World Bank expects upward pressure on commodity and agriculture prices to continue. Rising average global climate temperature and extreme weather patterns are expected to continue. 70% of all freshwater is already dedicated to traditional agriculture4. 25.9% of the global population experiences hunger or does not have regular access to nutritious and sufficient food 6. $1.7tn in annual economic cost of diet-related illness in US. The $100B toll of a pig epidemic in China. African Swine Fever in China is shaking up world trade flows⁹. WHO says that overuse of antibiotics in farming contributes to higher levels of its resistance in some human infections⁹. TM SCIENCE IN Moolec ALTERNATIVE PROTEINS 1 https://www.fao.org/worldfoodsituation/foodpricesindex/en/ 2 https://time.com/6162598/ukraine-war-food-shortage/ 3 https://www.mckinsey.com/-/media/mckinsey/industries/agriculture/our%20insights/reducing%20agriculture%20emissions%20through %20improved%20farming%20practices/agriculture-and-climate-change.pdf 4 https://www.worldbank.org/en/topic/water-in-agriculture#1 5 https://milkeninstitute.org/report/americas-obesity-crisis-health-and-economic-costs-excess-weight 6 https://www.who.int/docs/default-source/nutritionlibrary/publications/state-food-security-nutrition-2020-inbrief- en.pdf 7 https://www.fao.org/news/story/en/item/1402920/icode/ 8 https://gro-intelligence.com/insights/how-african-swine-fever-in-china-is-shaking-up-world-trade-flows 9 https://www.saveourantibiotics.org/the-issue/antibiotic-overuse-in-livestock-farming/ .14#15Plants Food System Overview Animals Soybean: most consumed meat analogue with the highest protein content Products Market: Billions 00 7 6 Global Meat Animal welfare claimed 5 to be the one of the 4 $1 trillion most important factors for consumers 3 USA & Argentina among the top 3 countries of soybean producers worldwide 25 kg Grain + 15.400 Its of water = 1 kg of meat Feed to food conversion inefficiency 77% of soybean production ends as feed for livestock for meat and dairy production Greenhouse Gas Emissions (GHG) from average food consumption TM SCIENCE IN Moolec ALTERNATIVE PROTEINS 1% 3% 4% 5% 7% 14% 19% 47% Meat Dairy production Poultry, fish, seafood, and eggs Sugars, oils, and fats Vegetables Fruits Grain Products Others 2 1 TY People Human population since 1800 1750 1800 1850 1900 1950 2000 2050 Years Highest population growth expected in developing countries with low GDP per capita Healthy diets are 5 times more expensive than diets that meet minimum energy levels Today 22% Consumers are vegetarian, vegan or flexitarians and growing 1 Sources: • FAO. The Contribution of Agriculture to Greenhouse Gas Emissions (February 2020) https://ahdb.org.uk/news/consumer-insight-understanding-consumers-attitudes-to-animal-welfare • https://ask.usda.gov/s/article/What-is-the-most-consumed-meat-in-the-world • https://ourworldindata.org/meat-production • https://ourworldindata.org/meat-production#global-meat-production https://population.un.org/wpp/ https://sniglobal.org/ https://www.fao.org/in-action/sustainable-and-circular-bioeconomy/resources/news/details/en/c/1459357 • https://www.foodnavigator.com/News/Promotional-Features/Taste-texture-and-nutritional-attributes-of-alternative-protein-products • https://www.un.org/en/academic-impact/97-billion-earth-2050-growth-rate-slowing-says-new-un-population-report • https://www.usda.gov/oce/commodity/wasde/wasde0922.pdf . • • https://www.who.int/docs/default-source/nutritionlibrary/publications/state-food-security-nutrition-2020-inbrief-en.pdf RethinkX. Rethinking Food and Agriculture 2020-2030. The Second Domestication of Plants and Animals, the Disruption of the Cow, and the Collapse of Industrial Livestock Farming WWF & Sustainability. Sustainable Food Systems and Diets: This review of multi-stakeholder initiatives (October 2018) https://www.researchandmarkets.com/reports/5633454/meat-products-global-market-opportunities-and? utm_source=GNOM&utm_medium=Press Release&utm_code=hfbkjw&utm_campaign=1739586+-+Global+Meat+Products+Market+Analysis%2c +Opportunities%2c+Forecasts%2c+and+Strategies+2016-2021%2c+2021-2026%2c+%26+2026-2031&utm_exec-chdo54prd .15#16Total Addressable Market¹ Massive opportunity to play in a double-digit growing industry (17% CAGR). $40B 2022 90% 72% $140B $300B 55% 28% 45% $65B 10% 2025 2030 Alternative Protein Traditional Meat Consumption Share (%) Alternative Meat Consumption Share (%) TM SCIENCE IN 1 Sources: Moolec ALTERNATIVE PROTEINS . Moolec's internal analysis based on publicly disclosed information for the industry primarily the GF1 State of Industry Report 2021 (March 2022) • United Nations, World Bank, Expert Interviews, A.T. Kearney Analysis 2035 .16#17Alternative Proteins Industry Emerging industry where companies use different technologies and ingredients based on plants, cells, and microbes to address the main food challenges. Plant-Based¹ Fermentation² Cultured Meat³ Products made from plants that are alternatives to animal-based products. This includes plant-based meat, seafood, eggs, and dairy. Use of intact live microorganisms to modulate and process plant-derived ingredient; the leverage of the fast growth and high protein content of microorganisms for efficient production. Genuine animal meat produced by cultivating animal cells directly. Made of the same cell types arranged in the same or similar structure as animal tissues, thus replicating sensory and nutritional profiles of conventional meat. https://gfi.org/science/the-science-of-plant-based-meat/ TM SCIENCE IN 2 Moolec https://gfi.org/science/the-science-of-fermentation/ ALTERNATIVE PROTEINS 3 https://gfi.org/science/the-science-of-cultivated-meat/ .17#18The challenge: Reach parity with animal-based food Taste and texture Nutritional values Scalability and low costs TM SCIENCE IN Moolec ALTERNATIVE PROTEINS .18#19The solution: Moolec as a Category Creator¹ Molecular Farming has the potential to overcome the main obstacles faced by other technologies in the alternative protein landscape. Taste and texture Nutritional values Scalability and low costs TM SCIENCE IN Moolec ALTERNATIVE PROTEINS Moolec TM Plant-based Fermentation Cultured meat Molecular Farming 1Sources: ☑ ✓ > Plants ✓ Science ☑ • https://www.studyfinds.org/taste-plant-based-diet/ • https://www.foodnavigator-asia.com/Article/2021/08/17/Plant-based-nutritional-pitfalls-Why-novel-products-don-t-necessarily-improve-diet-quality-Study • https://www.morningstarfarms.com/content/dam/North America/morningstarfarms/pdf/MSFPlantBased LCAReport_2016-04-10_Final.pdf • https://link.springer.com/article/10.1007/s11367-015-0931-6 • https://thecounter.org/lab-grown-cultivated-meat-cost-at-scale • https://gfi.org/wp-content/uploads/2021/03/cultured-meat-LCA-TEA-policy.pdf Plants + Science .19#20Molecular Farming Ecosystem¹ The industry is growing with stronger recognition of the advantages of Molecular Farming. Moolec is the only player focused on growing meat proteins in both soy and pea seeds. Nobell Foods Miruku3 VelozBio4 TM Moolec Dairy proteins in soybeans Dairy proteins in soybeans Dairy proteins in discarded fruit N →> POLOPO5 Mozza6 Dairy proteins in potatoes Dairy proteins in plants Dairy Moolec 米 米 Moolec Meat proteins in soybeans & pea t Kyomei? 000 Meat proteins in green leaves Meat Tiamat Sciences® Core Biogenesis Growth Factors Growth Factors ORF Genetics 10 BioBetter Growth Factors Growth Factors Growth Factors12 SCIENCE IN ALTERNATIVE PROTEINS 1 Moolec's internal analysis based on publicly disclosed information for the industry and management estimates 2 https://www.nobellfoods.com/ 3 https://miruku.com/ 4 https://velozbio.com 5 https://www.linkedin.com/company/polopo/about/ 6 https://www.mozzafoods.com/ 7 https://kyomei.co.uk/ 8 https://www.tiamat-sciences.com/ 9 https://corebiogenesis.com/ 10 https://www.orfgenetics.com/ https://biobetter.bio/ 12 Substance which is required from Cultured Meat Technology for the stimulation of growth in living cells .20#21The Technology Moolec TM SCIENCE IN ALTERNATIVE PROTEINS#22TM Moolec Traditional Molecular Farming SCIENCE IN ALTERNATIVE PROTEINS Animal Proteins in Plants Moolec introduces real animal genes in the plant's genome to give real taste and nutrition to food. Seeds об Crops Feed Livestock Seeds Crops Plant-based animal proteins Animal proteins - Genetic engineering Food Food Cruelty-Free .22#23Molecular Farming: a cost-effective way to produce alternative proteins Plants as Bioreactors We use plants as small factories, without extra energy cost using biology. TM SCIENCE IN Moolec ALTERNATIVE PROTEINS No extra purification cost We mix animal and plant proteins saving the extra purification cost. Economy of scale We use the hectares of farming to achieve volume, productivity and low costs. 1 Moolec's internal analysis based on publicly disclosed information for the industry and management estimates .23#24Moolec vs. Animal-based Production System Molecular Farming is more friendly to the environment when compared to traditional protein productive systems. TM SCIENCE IN Moolec ALTERNATIVE PROTEINS 35X less 1 8X less² 60X less³ Land Usage Water Footprint CO2 Emissions 1https://ourworldindata.org/agricultural-land-by-global-diets 2 https://waterfootprint.org/en/water-footprint/product-water-footprint/water-footprint-crop-and-animal-products/ 3 https://ourworldindata.org/food-choice-vs-eating-local .24#25Selection .01 Real DNA (protein of interest) is isolated Molecular Farming in a Nutshell до Gene is inserted into expression vector TM SCIENCE IN Moolec ALTERNATIVE PROTEINS 02 Transformation Development Scale-Up 03 Vector is inserted into plant chromosomes Cells expressing the desired proteins are selected and grown into cultures .04 .05 Engineered cells grow into whole plants Plants grow first in greenhouses and then at the fields 06 Production .07 Seeds are harvested and crushed Moolec Plant-based Animal Protein Ingredients .08 25#2690's =Sections Proof of Concept: Why Chymosin? Chymosin is a validation molecule in biotechnology by being the first protein for food been approved by the FDA with precision fermentation Fermentation Los Angeles Times SUBSCRIBE LOG IN IN Q FDA Approves 1st Genetically Engineered Product for Food L.A. TIMES ARCHIVES Molecular Farming 2010 MARCH 24.1990 12 AM PT FROM THE WASHINGTON POST WASHINGTON - The first genetically engineered product for human consumption, an enzyme expected to be of wide use in making cheese, was approved Friday by the Food and Drug Administration. In the decision, which came after 28 months of review, the agency said a bioengineered form of the enzyme rennin--which traditionally has been extracted from calves' stomachs as part of a mixture called rennet and used by cheese makers to curdle milk--presented no safety hazard and could be used in dairy products. Safflower Seeds "Groundbreaking Moment for Biotechnology" Plant-Based Bovine Protein Safflower Crops Bovine Gene Molecular Farming Moolec's team achieved the same with plants' TM SCIENCE IN 1 This milestone was achieved by a Team within Bioceres Group, Moolec's predecessor company Moolec ALTERNATIVE PROTEINS Cheese ingredient .26#27Moolec TM SCIENCE IN ALTERNATIVE PROTEINS Transferrable & scalable technology Based on our Proof of Concept we were able to extend our technology to new hosts with enhanced features. PATENT PENDING PATENT PENDING T PENDING PATENT Plant-Based Chymosin Safflower Soy Protein content 20% Scalability Yield 120K has 1 ton/ha Market 350M Chymosin 40% 50M has 5 ton/ha 1.5B Meat Replacement Soy proteins Meat Proteins .27#28Fermentation: Our Validation Platform Precision fermentation complements Molecular Farming technology as validation stage and faster go-to-market pathway. Technological Strategy Validation Stage / Low Scale Stage 1: Fermentation - Strategic Joint Venture TM SCIENCE IN Moolec ALTERNATIVE PROTEINS Fast application testing ✓ Quick regulatory footprint ✓ IP discovery Partnerships and commercial opportunities ✓ Product development grupoINSUD Expansion Stage / High Scale Stage 2: Molecular Farming .28#29)། Pipeline & Products Moolec TM SCIENCE IN ALTERNATIVE PROTEINS#30PROGRAM Dairy ingredient and Nutritional oil (Chymosin & GLA) Meat Replacement (POORK+ Pipeline Status R&D OPERATIONS HOST PROJECT PHASE¹ PLANED COMMERCIAL REGULATION SAM² 2025 DISCOVERY PROOF OF CONCEPT EARLY ADVANCED DEVELOPMENT DEVELOPMENT PRE-LAUNCH PRODUCT LAUNCH LAUNCH STATUS SPC2 Safflower GLASO YEEA1 1 Yeast YEEA2 1 YEEA3 2 SOOY1 3 & BEEF+) SOOY2 3 Soybean SOOY3 3 SOOY4 4 Pea PEEA1 3 2 Serviceable Available Market 1 Refers to different phases of meat replacing process TM SCIENCE IN Moolec ALTERNATIVE PROTEINS 3 Moolec internal analysis based on Global Rennet Market 2022-2027 - Mordor Intelligence 4 Moolec internal analysis based on Global Gamma Linolenic Acid market. Market size, status and forecast to 2028 - Verified Market Research 5 Moolec internal analysis based on Plant-based Ingredients Market 2021 - MarketsAndMarkets 2025 2025 2025 2025 2026 350M³ 1.5B4 2027 1.5B5 2029 2029 TBD 2028 .30#31Plant-Based Meat Ingredients by Weight Alternative meat industry still uses traditional ingredients, limiting it from overcoming major challenges and meeting consumer expectations. Current industry challenges × Not clean label. 20+ different components × Not fully natural. Synthetic and chemical additives × Not the same nutritional values to animal-based TM SCIENCE IN 1 Sources: Moolec ALTERNATIVE PROTEINS • Flavouring & Appearance 50% Water 5% 5% Binding & Texturizing 20% Plant Proteins 20% Sunflower & Coconut Oils Bakhsh, A.; Lee, S. - J.; Lee, E. - Y.; Hwang, Y. - H.; Joo, S. - T. Characteristics of Beef Patties Substituted by Different Levels of Textured Vegetable Protein and Taste Traits Assessed by Electronic Tongue System. Foods 2021, 10, 2811. https://doi.org/10.3390/foods10112811 Annotated with internal analysis of nutritional data of market available products (NL). .31#32Moolec's Substitute Process by Cost¹ PHASE 1 PHASE 2 PHASE 3 PHASE 4 50% Flavouring & Appearance + 15% + 14% + 20% 99% Binding & Texturizing Plant Proteins Sunflower of the & Coconut Oils cost Current industry challenges × Not clean label. 20+ different components × Not fully natural. Synthetic and chemical additives ✓ Not the same nutritional values to animal-based With Moolec's Technology Clean label approach Real animal protein genes Healthier nutritional values TM SCIENCE IN Moolec ALTERNATIVE PROTEINS PHASE 1 1% Water 50% Flavouring & Appearance 1 Phases included refer to the information displayed on Slide 30. Moolec takes all necessary action to respect all intellectual property rights. 20% Sunflower & Coconut Oils 15% Binding 14% & Texturizing Plant Proteins PHASE 2 .32#33再 Chyrosin SPC Moolec Chymosin SPC Product Portfolio Enhanced plant-based ingredients with real animal proteins inside¹. Safflower GLA SONOVA Moolec 14 GLA SONOVAⓇ Soy BEEEXLABLE POUCH POORK+ SOY+PORK CRUELTY-FREE Moolec Pea REGENKABLE POOCH BEEF+ PEA+BEEF CRUELTY-FREE Moolec Dairy Ingredient Plant-based chymosin, a key ingredient for cheese production compulsory for the clotting step. Nutritional Oil Plant-based GLA oil destined for enriching food, nutraceutical products, and pet food². Meat Replacement Plant-based real porcine proteins embedded within the matrix of native soy proteins to enhance alternative meat products. Meat Replacement Plant-based real bovine proteins embedded within the matrix of native pea proteins to enhance alternative meat products. Texture TM SCIENCE IN Moolec ALTERNATIVE PROTEINS Nutrition³ Sensory4/Nutrition³ Sensory4/Nutrition³ 1 Applies to plant-based Chymosin, POORK+ and BEEF+ products. GLA is a plant-based nutritional oil 2 The FDA has approved the GLA-containing safflower seed oil as a new ingredient in dietary supplements, nutritional beverages, and medicinal foods for humans. The FDA has also approved the use of the seed oil as an ingredient in dog and cat food and the use of the seed meal in cattle and poultry feeds. Moolec is conducting pre-submission consultation with the FDA with respect to additional uses in food products for humans and animals 3 Nutrition can refer to a superior digestibility of the expressed protein or any improved micronutrient content and subsequent bioavailability 4 Sensory implies an improved perception after inclusion into the formulation of a specific food product such as meat replacers .33#34Today most consumers accept GMO Food 98% of all soybeans grown in the USA are GMO, and Impossible Burger's successful rollout confirmed that GMO is no longer a material issue in the US consumer's minds 12. FOOD DIVE Deep Dive Opinion Library Events Finances & Deals Food Tech Manufacturing Ingredients Corporate Ops Packaging Policy Protein GMO labeling not likely to impact purchase decisions, study says Research found voluntary certification from the Non-GMO Project had a greater influence on consumers than the type of mandatory disclosure that went into effect this week. Published Jan. 5, 2022 Megan Poinski Senior Reporter DERI ERIVE FROM ERING DENGINEE 20 Retrieved from US Department of Agricdes TM SCIENCE IN Moolec ALTERNATIVE PROTEINS BIOENG in 8 – 90% ALLIANCE FOR SCIENCE Who We Are Ars Live! Training News & Views Research Resources Q DONATE Anti-GMO themes losing traction worldwide, suggests new scientific NEWS U paper BY AFS STAFF MARCH 30, 2022 90% 83 83% 80% 75% 75% 78% 726 70% 66% 60% 50% 40% Feb-18 Aug-18 Sep-18 X8-18 67% Dac-18 Feb-18 Share 81% 47% 48% 75% 75% 74% Sep-19 04-19 No-19 -Favorability -Linear (Favorability) R=0.0438 89% 22% 20 90% 84% 80% 76% 7 67% 64% 63% Aug-20 Sep-20 1 https://www.fooddive.com/news/gmo-labeling-not-likely-to-impact-purchase-decisions-study-says/616452/ 2 https://allianceforscience.cornell.edu/blog/2022/03/anti-gmo-themes-losing-traction-worldwide-suggests-new-scientific-paper/ 3 https://gm4good.org/ Nov-20 75% Transparency and the cause's purpose are key Discussion gravitates around science, hunger and climate change. Moolec promotes a new scientific movement³: GM4✓ GOOD GM4GOOD.ORG .34#35Regulatory Pathway Moolec is subject to the laws and regulations governing biotechnology and food companies in the jurisdictions in which we operate. Regulation of Plant Biotechnology Products USDA United States Department of Agriculture USDA APHIS FDA U.S. FOOD & DRUG ADMINISTRATION Ministerio de Agricultura, Ganadería y Pesca Argentina TM Moolec SCIENCE IN ALTERNATIVE PROTEINS COMMISSION Regulation of Food and Ingredient Products * UNITED MCMXN AMERICA UNITED ENVIRONMENTAL FDA U.S. FOOD & DRUG ADMINISTRATION OSHA Occupational Safety and Health Administration STATES AGENCY PROTECTION USDA United States Department of Agriculture Other Regulatory Requirements Subject regulations and requirements related to: Safe working conditions. • Laboratory and distribution practices. • Transportation • Disposal of hazardous or potentially hazardous substances Cross-border transit of finished goods and raw materials .35#36TM SCIENCE IN Moolec ALTERNATIVE PROTEINS Patent Portfolio Moolec stands on a strong and growing IP strategy with great understanding of the biotech landscape offering a competitive advantage on its execution. DATENTED PATENTED PATENTED⭑ GLA PATENT PENDING Chymosin SPC PATENT APPLICATION New Filings Australia United States Mexico Argentina Japan # Patt 1 Canada Brasil Italy France Germany UK Spain Hong Kong New ealand China Malaysia Argentina Australia Canada Italy United States Mexico Brasil France United States atents Germany UK 2Patents .36#3729/20 WP-001543-0018 W82-ISU-01 Latest Milestones Soybean T1 seed harvested. Next phase for achieving T2 & T3 seeds started August 2022 Sample of seed protein SN ΤΑ extract expressing № 22 2 protein of interest 73 Pea Ongoing transformation and regeneration stage Chymosin SPC Planted in Córdoba, Argentina June 2022 GLA Planted in Idaho Falls, USA, harvested October 2022 SPC × GLA Back Crossing 1 finished. Back Crossing 2 started June 2022 Fermentation platform 1st yeast-based prototype for meaty flavor TM SCIENCE IN Moolec ALTERNATIVE PROTEINS GLA GLA CAPTIO DC .37#38)། Environmental, social and governance (ESG) Moolec TM SCIENCE IN ALTERNATIVE PROTEINS#39Moolec addresses directly 10 of the 17 SDGs We use SDGs and 2030 Agenda as guidelines to strategically align our business in the search of the building of a more equitable, resilent and sustainable food system 12. Moolec HUNGER SUSTAINABLE 2 ZERO DEVELOPMENT GOALS SSS TM 3 GOOD HEALTH AND WELL-BEING W 6 CLEAN WATER AND SANITATION 7 AFFORDABLE AND CLEAN ENERGY DECENT AND REDUCED 8 ECONOMIC GROWTH 10 NEQUALITIES M RESPONSIBLE 12 CONSUMPTION AND PRODUCTION GO CLIMATE 13 ACTION LIFE 14 BELOW WATER LIFE 15 ON LAND TM SCIENCE IN Moolec ALTERNATIVE PROTEINS https://sdgcompass.org/ 2 http://www.fao.org/documents/card/en/c/09a43cf2-c53a-40fe-bf4aa7f87236b2ce/ 13 PARTNERSHIPS FOR THE GOALS M NO POVERTY LIFE 15 LIFE ON LAND 14 BELOW WATER 16 PEACE, JUSTICE AND STRONG INSTITUTIONS Forests contain over 80% of the world's terrestrial biodiversity Fish gives 3 bn people 20% of daily animal protein CLIMATE ACTION Agriculture is key in responding t dimate change Ending hunger can contribute greatly to peace and stability Partnerships help raise the voice of the hungry Almost 80% of poor people live in rural areas ZERO 2 HUNGER We produce food for everyone, yet almost 800 million go hungry FOOD AND AGRICULTURE 555 3 GOOD HEALTH AND WELL-BEING Good health starts with nutrition Nutritious food is critical to learning Women produce 1/2 the world's food but have much less access to land QUALITY 4 EDUCATION сл 12 RESPONSIBLE CONSUMPTION 1/3 of the food we AND PRODUCTION QO produce is lost or wasted Rural investment con deter unmanageable urbanization SUSTAINABLE CITIES AND COMMUNITIES GENDER EQUALITY From ending poverty, hunger to responding to climate change, food and agriculture lie at the very heart of the 2030 Agenda for Sustainable Development. Sustainable agriculture has the potential to address water scarcity CLEAN WATER AND SANITATION Modern food systems developing countries Agricultural growth in low-income economies con reduce poverty by half are heavily dependent on fossil fuels DECENT WORK AND AFFORDABLE AND CLEAN ENERGY Land reforms can give fairer access Agriculture in accounts to rural land 10 REDUCED INEQUALITIES for 1/4 of GOP INDUSTRY, INNOVATION AND INFRASTRUCTURE ECONOMIC GROWTH .39#40Enviromental & Social Impact¹ Moolec's technology is much more friendly to the environment and promotes an inclusive global value chain, bringing farmers back to the equation. Main Concept Water usage Energy eficiency GHG Emisions Carbon capture Workforce inclusion 1 Sources: TM • SCIENCE IN Moolec • ALTERNATIVE PROTEINS Fermentation TM Moolec Cultured meat Molecular Farming Medium High Medium Low ✓ Low ✓ Low High ✓ High ✓ High Low ✓ Negative ✓ Negative Positive Medium ✓ Low High • https://www.studyfinds.org/taste-plant-based-diet/ https://www.foodnavigator-asia.com/Article/2021/08/17/Plant-based-nutritional-pitfalls-Why-novel-products-don-t-necessarily-improve-diet-quality-Study https://www.morningstarfarms.com/content/dam/NorthAmerica/morningstarfarms/pdf/MSFPlantBased LCAReport_2016-04-10_Final.pdf • • https://link.springer.com/article/10.1007/s11367-015-0931-6 . https://thecounter.org/lab-grown-cultivated-meat-cost-at-scale https://gfi.org/wp-content/uploads/2021/03/cultured-meat-LCA-TEA-policy.pdf .40#41Focused on using all parts of the plants' We create sustainable products and by-products following circular supplies and resource recovery strategies². Plant & animal protein for main product 01 Leaves for carbon sequestration 05 and soil composting TM SCIENCE IN Moolec 2 ALTERNATIVE PROTEINS Fiber as source for renewable energy 04 02 02 Oils as high-valued by-product 03 Starches for feed and/or bioplastics Information displayed in this chart is an example on what potential uses of the different parts of the plant can be destined for. https://www.accenture.com/t20150523t053139_w_/us-en/_acnmedia/accenture/conversion-assets/dotcom/documents/global/pdf/strategy_6/accenture-circular-advantage- innovative-business-models-technologies-value-growth.pdf .41#42)། Appendix Moolec TM SCIENCE IN ALTERNATIVE PROTEINS#43Transaction Overview - Capitalization, Sources, and Uses Transaction Sources and Uses Sources Redemptions Scenarios Pro-Forma Valuation Redemptions Scenarios 0% 50% 100% 0% 50% 100% SPAC cash in trust¹ $27.7 M 8 Moolec shares (rollover equity) Backstop $325.0 M $0.0 M $13.8 M $325.0 M $0.0 M $0.0 M $325.0 M $10.0 M Pro-Forma Shares Outstanding" Illustrative Share Price 1, 3 MM shares $/share 39.3 37.9 $10.0 $10.0 37.69 $10.0 Pro Forma Equity Value $393.3 M $379.5 M $375.6 M Total Sources $352.7 M $338.8 M $335.0 M Uses Cash to Surviving Company Balance Sheet $16.0 M Moolec shares (rollover equity) Estimated transaction costs² Total Uses TM SCIENCE IN Moolec ALTERNATIVE PROTEINS 0% 50% 100% $325.0 M $11.7 M $4.5 M $325.0 M $9.3 M (-) Pro-Forma Cash to Surviving Company Balance Sheet¹ 2 (+) Pro-Forma Net Debt $3.4 M $325.0 M $6.6 M -$16.0 M $0.0 M -$4.5 M $0.0 M -$3.4 M $0.0 M Pro-Forma Enterprise Value $377.3 M $375.0 M $372.2 M $352.7 M $338.8 M $335.0 M Pro-Forma Ownership1, 3 MM Shares Redemptions Scenarios 0% 50% 100% Existing Shareholders4 31.0 78.7% 31.0 81.7% 31.3 83.3% LJAQ Public Stockholders 2.8 7.0% 1.4 3.7% 0.0 0.0% Initial Stockholders5 2.5 6.5% 2.5 6.7% 3.0 8.1% New Company Shareholders 10 Other Investors6 Total 1.5 3.8% 1.5 4.0% 1.5 4.0% 1.5 3.9% 1.5 4.0% 1.8 4.8% 39.3 99.9% 37.9 100.1% 37.69 100.2% 1 Assumes different redemptions scenarios from LJAQ Investors consider that balance of the Trust Account was reduced from $138 M as of June 30, 2022, to $28 M as of July 12, 2022; actual redemptions may differ 2 Estimated transaction costs paid in cash (excludes expenses paid with equity); final expenses will differ depending on negotiations 3 Excludes private & public warrants, transaction costs paid with equity post-closing, and management equity plan 4 Includes original Moolec shareholders 5 Refers to LJAQ Sponsor shares and ordinary shares issued to EarlyBird in connection with the IPO 6 Includes shares from Moolec SAFE holders that entail Theo I SCSp, third-party investors, and shares from other equity commitments 7 Assumes any existing debt will be canceled or prepaid at closing 8 LJAQ has entered into a backstop agreement with entities affiliated with Moolec to guarantee a $10M minimum cash condition at closing 9 Number of shares could differ depending on backstop agreement implementation 10 Reflects certain shareholders of Bioceres S.A. and Bioceres Group PLC that will receive a new issuance of Company Ordinary Shares, prior to the business combination, that will be exchanged for Holdco Ordinary Shares .43#44Number of Shares Latest Detail Pro-Forma Ownership 0%¹ 50%¹ 100%1, 2 BG Farming Technologies Limited 14,570,000 37.0% Union Group Ventures Ltd. Bioceres Crop Solutions Corp. 14,570,000 1,860,000 37.0% 4.7% 14,570,000 14,570,000 1,860,000 38.4% 38.4% 4.9% 1,860,000 New Company Shareholders³ 1,500,000 3.8% 1,500,000 4.0% 1,500,000 14,570,000 38.8% 14,820,0005,8 39.5% 5.0% 4.0% Company SAFE Holders 262,260 0.7% 262,260 0.7% 512,2606,8 1.4% Initial Stockholders4 2,535,000 6.5% 2,535,000 6.7% 3,035,0007,8 8.1% LightJump Public Stockholders 2,767,210 7.0% 1,383,605 3.7% 0.0% Key Staff Participation 232,523 0.6% UG Holdings LLC 1,035,000 2.6% 232,523 1,035,000 0.6% 232,523 0.6% 2.7% 1,035,000 2.8% Total 39,331,993 99.9% 37,948,388 100.1% 37,564,783 100.2% TM SCIENCE IN Moolec ALTERNATIVE PROTEINS 1 Does not reflect any shares to be issued following Closing pursuant to (i) the EarlyBird Share Fee or (ii) any equity securities to be granted pursuant to any management or employee share plans. 2 Assumes that the obligations under the Backstop Agreement are satisfied through a cash constribution to Holdco, including, (i) the Sponsor provides $5,000,000 in cash to Holdco, (ii) Union Group Ventures Ltd. provides $2,500,000 incash to Holdco and (iii) Theo | SCSp provides $2,500,000 in cash to Holdco. 3 Reflects certain shareholders of Bioceres S.A. and Bioceres Group PLC that will receive a new issuance of Company Ordinary Shares, prior to the business combination, that will be exchanged for Holdco Ordinary Shares 4 Includes 2,415,000 held by the Sponsor and 120,000 ordinary shares issued to EarlyBird in connection with the IPO. 5 Reflects an additional 250,000 Holdo Ordinary Shares to be issued to Union Group Ventures Ltd. in connection with the BackstopAgreement. 6 Reflects an additional 250,000 Holdco Ordinary Shares to be issued to Theo ISCSp in connection with the Backstop Agreement. 7 Reflects anadditional 500,000 Holdco Ordinary Shares to be issued to Sponsor in connection with the Backstop Agreement. 8 In scenarios where a sufficient number of holders of Public Shares of SPAC Common Stock redeem their shares and the obligations under the Backstop Agreement are triggered, which would occur if the Net Available Assets minus the EarlyBird fee is less than $10,000,000, many variations of the ownership of Holdco Ordinary Shares post-closing are possible .44#45M GEZTEHS E1 Let's empower science in food for the Moolec TM re @food hac Moolec food er's - in Follow us! www.moolecscience.com